Dihydroergotamine Mesylate Spray
NDC Package 73352-096-19
Package Information
Dihydroergotamine Mesylate sprays is a medication used to treat migraine headache attacks. This formulation utilizes a spray delivery system. Marketed by Trifluent Pharma, Llc, this product is identified by NDC 73352-096 and is authorized under FDA application ANDA216881.
Identification & Billing
- RxCUI: 861668 - dihydroergotamine mesylate 4 MG/mL Metered Dose Nasal Spray
- RxCUI: 861668 - dihydroergotamine mesylate 0.5 MG/ACTUAT Metered Dose Nasal Spray
- RxCUI: 861668 - DHE Mesylate 0.5 MG/ACTUAT Metered Dose Nasal Spray
- RxCUI: 861668 - dihydroergotamine mesylate 0.5 MG/ACTUAT (4 MG/ML) Metered Dose Nasal Spray
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73352 - Trifluent Pharma, Llc
- 73352-096 - Dihydroergotamine Mesylate
- 73352-096-19 - 8 KIT in 1 KIT / 1 VIAL, GLASS in 1 KIT (73352-096-18) / 1 mL in 1 VIAL, GLASS
- 73352-096 - Dihydroergotamine Mesylate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73352-096-19 identifies a specific commercial package of 8 kit in 1 kit / 1 vial, glass in 1 kit (73352-096-18) / 1 ml in 1 vial, glass of Dihydroergotamine Mesylate, a human prescription drug labeled by Trifluent Pharma, Llc. This spray is formulated for nasal use and contains dihydroergotamine mesylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Trifluent Pharma, Llc on July 08, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat migraine headache attacks. It helps relieve headache pain and other symptoms such as sensitivity to light or sound. Prompt treatment allows you to get back to your normal routine sooner and may decrease your need for other pain medications. This medication is not used to prevent migraines from occurring. Dihydroergotamine belongs to a class of drugs known as ergot alkaloids. It may work by narrowing the blood vessels in the brain. It may also block other pain pathways in the brain.
How is this Trifluent Pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73352009619. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.